NCT03826784View on ClinicalTrials.gov

Bone Healing Accelerant Versus Standard of Care for Open Tibia Fractures

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2019

Primary Completion Date

January 31, 2022

Study Completion Date

February 28, 2022

Conditions
Tibial Fractures
Interventions
COMBINATION_PRODUCT

BHA

BHA active ingredients include a blood-derived component and beta-tricalcium phosphate. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.

Trial Locations (1)

15203

Carmell Therapeutics, Pittsburgh

Sponsors
All Listed Sponsors
lead

Carmell Therapeutics Corporation

INDUSTRY